VCYT Q4 2022 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$80M+19.2% YoY

Gross Profit

$53M66.6% margin

Operating Income

-$5M-6.7% margin

Net Income

-$4M-4.8% margin

EPS (Diluted)

$-0.05

QoQ Revenue Growth

+6.2%

Cash Flow

Operating Cash Flow

$10M

Free Cash Flow

$8M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$81M

Stockholders' Equity

$1.1B

Cash & Equivalents

$154M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$80M	$67M	+19.2%
Gross Profit	$53M	$44M	+20.3%
Operating Income	-$5M	-$12M	+56.1%
Net Income	-$4M	-$11M	+63.5%

Revenue Segments

Testing

$70M88%

Biopharmaceutical And Other

$7M8%

Product

$3M4%